Biomarker Tests: Delaware’s New Play for Cancer Care

Delaware lawmakers are weighing a bill that would require health plans, including Medicaid, to cover comprehensive biomarker testing—a diagnostic tool that examines a patient’s cells for clues guiding the most effective treatments.

Why Biomarker Testing Matters

• Precision Medicine: Knowing a tumor’s unique features lets doctors select therapies that are more likely to work and avoid ineffective, side‑effect‑heavy options.
• Improved Survival: Studies show biomarker‑guided care boosts survival rates, even for aggressive cancers like lung and breast cancer.
• Beyond Oncology: Tests also aid in diagnosing arthritis, autoimmune disorders, and organ transplant compatibility. New medicines from clinical trials often rely on these tests to target the right patients.

Current Coverage Gap

• Only 25% Covered: Roughly one‑quarter of Delaware residents have insurance plans that do not cover these essential tests.
• Disparities Persist: Coverage gaps disproportionately affect Black patients, Medicaid recipients, and lower‑income groups, widening existing health inequities.
• Risk of Growing Inequity: Without action, disparities in access to precision medicine will deepen.

Potential Impact of the Bill

• Join 23 States: Delaware could become one of many states already offering biomarker coverage, improving outcomes for cancer patients.
• Clinical Trial Access: Coverage would open doors to cutting‑edge clinical trials, benefiting a broader patient population.
• Equity Advancement: The bill could reduce racial and socioeconomic disparities in cancer care.

Legislative Momentum

• Governor Meyer’s Support: The governor highlighted the bill’s importance in his budget speech.
• Active Advocacy: Senators and representatives are pushing forward, aiming to give Delawareans a fair shot at precision medicine.